340B drugs drop to ASP minus 28 percent, ASC weight falls to 0.814
Oct 28, 2026 – Nov 15, 2026
-
340B outpatient cut awaits final rule
CMS's July 2 proposed 2027 OPPS rule would pay 340B-purchased drugs at average sales price minus 33.4 percent, with a trade-press estimate of a $4.55 billion first-year cut in Medicare drug payments redistributed to non-drug services, and the final rule is expected later this year.
Read this issue → -
340B drug payments cut in final rule
CMS's final 2027 hospital outpatient rule aligns Medicare payment for 340B drugs with acquisition cost, estimating $5.45 billion less drug spending in 2027, and moves off-campus imaging without contrast to the fee schedule rate.
Read this issue → -
340B cut finalized at ASP minus 28 percent
CMS's final CY2027 hospital outpatient rule pays 340B-purchased drugs at average sales price minus 28 percent from January 1, softer than the 33.4 percent proposed in July, with a $4.35 billion first-year drug payment cut and the remedy offset rising to 2 percent a year until $7.8 billion is recovered.
Read this issue → -
340B drugs drop to ASP minus 28 percent, ASC weight falls to 0.814
The final 2027 outpatient rule pays 340B-acquired drugs at average sales price minus 28 percent from January 1, against 33.4 percent proposed, and cuts the surgery center payment weight scalar from 0.872 to 0.814.
Read this issue →